144 related articles for article (PubMed ID: 37463241)
21. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
22. H3K36me2 methyltransferase NSD2 orchestrates epigenetic reprogramming during spermatogenesis.
Li Z; Zhang X; Xie S; Liu X; Fei C; Huang X; Tang Y; Zhou LQ
Nucleic Acids Res; 2022 Jul; 50(12):6786-6800. PubMed ID: 35736136
[TBL] [Abstract][Full Text] [Related]
23. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma.
Osada N; Kikuchi J; Iha H; Yasui H; Ikeda S; Takahashi N; Furukawa Y
Clin Transl Med; 2023 Aug; 13(8):e1364. PubMed ID: 37581569
[TBL] [Abstract][Full Text] [Related]
24. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
[TBL] [Abstract][Full Text] [Related]
25. A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization.
Dilworth D; Hanley RP; Ferreira de Freitas R; Allali-Hassani A; Zhou M; Mehta N; Marunde MR; Ackloo S; Carvalho Machado RA; Khalili Yazdi A; Owens DDG; Vu V; Nie DY; Alqazzaz M; Marcon E; Li F; Chau I; Bolotokova A; Qin S; Lei M; Liu Y; Szewczyk MM; Dong A; Kazemzadeh S; Abramyan T; Popova IK; Hall NW; Meiners MJ; Cheek MA; Gibson E; Kireev D; Greenblatt JF; Keogh MC; Min J; Brown PJ; Vedadi M; Arrowsmith CH; Barsyte-Lovejoy D; James LI; Schapira M
Nat Chem Biol; 2022 Jan; 18(1):56-63. PubMed ID: 34782742
[TBL] [Abstract][Full Text] [Related]
26. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
27. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
[TBL] [Abstract][Full Text] [Related]
28. Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma.
Herviou L; Ovejero S; Izard F; Karmous-Gadacha O; Gourzones C; Bellanger C; De Smedt E; Ma A; Vincent L; Cartron G; Jin J; De Bruyne E; Grimaud C; Julien E; Moreaux J
Clin Epigenetics; 2021 Sep; 13(1):174. PubMed ID: 34530900
[TBL] [Abstract][Full Text] [Related]
29. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
[TBL] [Abstract][Full Text] [Related]
30. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
31. Histone methyltransferase Nsd2 is required for follicular helper T cell differentiation.
Long X; Zhang L; Zhang Y; Min M; Lin B; Chen J; Ma X; Zhai S; Cai Z; Liu Y; Lu Y; Che N; Tan W; Qin J; Wang X
J Exp Med; 2020 Jan; 217(1):. PubMed ID: 31636135
[TBL] [Abstract][Full Text] [Related]
32. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
33. SETDB1 induces lenalidomide resistance in multiple myeloma cells via epithelial‑mesenchymal transition and PI3K/AKT pathway activation.
Qian X; Yang Y; Deng Y; Liu Y; Zhou Y; Han F; Xu Y; Yuan H
Exp Ther Med; 2023 Jun; 25(6):274. PubMed ID: 37206551
[TBL] [Abstract][Full Text] [Related]
34. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
36. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
37. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Herviou L; Kassambara A; Boireau S; Robert N; Requirand G; Müller-Tidow C; Vincent L; Seckinger A; Goldschmidt H; Cartron G; Hose D; Cavalli G; Moreaux J
Clin Epigenetics; 2018 Oct; 10(1):121. PubMed ID: 30285865
[TBL] [Abstract][Full Text] [Related]
38. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma.
Fuchs O
Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):16-34. PubMed ID: 23534949
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
40. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
